| Dr Sima Assefi, MD | |
|
1801 Butler Pike, Apt 159, Conshohocken, PA 19428-3156 | |
| (484) 532-7480 | |
| Not Available |
| Full Name | Dr Sima Assefi |
|---|---|
| Gender | Female |
| Speciality | Family Practice |
| Experience | 26 Years |
| Location | 1801 Butler Pike, Conshohocken, Pennsylvania |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1417260027 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | MT198052 (Pennsylvania) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Tower Health Urgent Care, Llc | 2668716069 | 87 |
News Archive
SANUWAVE Health, Inc., today announced the publication of peer-reviewed, preclinical research that demonstrates the ability of the Company's Extracorporeal Shock Wave Technology (ESWT) to stimulate proliferation of periosteal adult stem cells (cambium cells) within the body and subsequently form bone.
One of the strangest things about the H.I.V. epidemic in the Deep South-;from Louisiana to Alabama to Mississippi-;is how easily most Americans have elided it, choosing instead to imagine that the disease is now an out-there, elsewhere epidemic.
A study, by Dr Julian Trollor and Dr Tracy Anderson from the School of Psychiatry at UNSW, found that elderly participants (those aged 65 and above) reported a lower prevalence of psychiatric and anxiety disorders and had lower levels of psychological distress than middle-aged participants.
Molecular Detection Inc. (MDI), a company developing Detect-Ready™ tests designed to increase the speed and accuracy of infectious disease diagnosis, and life sciences and diagnostics distributor Westburg BV today announced that they have entered into an exclusive agreement for distribution of MDI's Detect-Ready MRSA panel in the Benelux region.
ARIAD Pharmaceuticals, Inc. (Nasdaq: ARIA) today announced data from a Phase 1 clinical trial evaluating oral ridaforolimus, its investigational mTOR inhibitor, in combination with bevacizumab (Avastin®) in heavily pretreated patients with refractory metastatic solid tumors. The data were presented at the Joint Multidisciplinary Congress of the 15th annual European Cancer Organization (ECCO) and the 34th annual European Society of Medical Oncology (ESMO) taking place in Berlin, Germany.
› Verified 8 days ago
| Entity Name | Tower Health Urgent Care, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1194293647 PECOS PAC ID: 2668716069 Enrollment ID: O20181211002273 |
News Archive
SANUWAVE Health, Inc., today announced the publication of peer-reviewed, preclinical research that demonstrates the ability of the Company's Extracorporeal Shock Wave Technology (ESWT) to stimulate proliferation of periosteal adult stem cells (cambium cells) within the body and subsequently form bone.
One of the strangest things about the H.I.V. epidemic in the Deep South-;from Louisiana to Alabama to Mississippi-;is how easily most Americans have elided it, choosing instead to imagine that the disease is now an out-there, elsewhere epidemic.
A study, by Dr Julian Trollor and Dr Tracy Anderson from the School of Psychiatry at UNSW, found that elderly participants (those aged 65 and above) reported a lower prevalence of psychiatric and anxiety disorders and had lower levels of psychological distress than middle-aged participants.
Molecular Detection Inc. (MDI), a company developing Detect-Ready™ tests designed to increase the speed and accuracy of infectious disease diagnosis, and life sciences and diagnostics distributor Westburg BV today announced that they have entered into an exclusive agreement for distribution of MDI's Detect-Ready MRSA panel in the Benelux region.
ARIAD Pharmaceuticals, Inc. (Nasdaq: ARIA) today announced data from a Phase 1 clinical trial evaluating oral ridaforolimus, its investigational mTOR inhibitor, in combination with bevacizumab (Avastin®) in heavily pretreated patients with refractory metastatic solid tumors. The data were presented at the Joint Multidisciplinary Congress of the 15th annual European Cancer Organization (ECCO) and the 34th annual European Society of Medical Oncology (ESMO) taking place in Berlin, Germany.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Sima Assefi, MD 1801 Butler Pike, Apt 159, Conshohocken, PA 19428-3156 Ph: (484) 532-7480 | Dr Sima Assefi, MD 1801 Butler Pike, Apt 159, Conshohocken, PA 19428-3156 Ph: (484) 532-7480 |
News Archive
SANUWAVE Health, Inc., today announced the publication of peer-reviewed, preclinical research that demonstrates the ability of the Company's Extracorporeal Shock Wave Technology (ESWT) to stimulate proliferation of periosteal adult stem cells (cambium cells) within the body and subsequently form bone.
One of the strangest things about the H.I.V. epidemic in the Deep South-;from Louisiana to Alabama to Mississippi-;is how easily most Americans have elided it, choosing instead to imagine that the disease is now an out-there, elsewhere epidemic.
A study, by Dr Julian Trollor and Dr Tracy Anderson from the School of Psychiatry at UNSW, found that elderly participants (those aged 65 and above) reported a lower prevalence of psychiatric and anxiety disorders and had lower levels of psychological distress than middle-aged participants.
Molecular Detection Inc. (MDI), a company developing Detect-Ready™ tests designed to increase the speed and accuracy of infectious disease diagnosis, and life sciences and diagnostics distributor Westburg BV today announced that they have entered into an exclusive agreement for distribution of MDI's Detect-Ready MRSA panel in the Benelux region.
ARIAD Pharmaceuticals, Inc. (Nasdaq: ARIA) today announced data from a Phase 1 clinical trial evaluating oral ridaforolimus, its investigational mTOR inhibitor, in combination with bevacizumab (Avastin®) in heavily pretreated patients with refractory metastatic solid tumors. The data were presented at the Joint Multidisciplinary Congress of the 15th annual European Cancer Organization (ECCO) and the 34th annual European Society of Medical Oncology (ESMO) taking place in Berlin, Germany.
› Verified 8 days ago
Mrs. Ritamarie Mancini Clarke, DO Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 700 Fayette Street, Conshohocken, PA 19428 Phone: 610-828-0358 Fax: 610-825-9665 | |
Kristie Beth Nichols, MD Family Medicine Medicare: Medicare Enrolled Practice Location: 1100 E Hector St, Suite 105, Conshohocken, PA 19428 Phone: 610-828-2608 Fax: 610-828-0102 | |
Harry A Frankel, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1100 E Hector St, Suite 105, Conshohocken, PA 19428 Phone: 610-828-2608 Fax: 610-828-0102 | |
Dr. Glenn Miller Jr., D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 700 Fayette St, Conshohocken, PA 19428 Phone: 610-828-0358 | |
John Lembeck, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1100 E Hector St, Ste 105, Conshohocken, PA 19428 Phone: 610-828-2608 Fax: 610-828-0102 | |
Kenneth J Varano, DO Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 125 E Elm St Ste 201, Conshohocken, PA 19428 Phone: 215-892-1230 Fax: 610-910-3890 |